Skip to main contentAll people

Associate ProfessorKatrin Sjoquist

Clinical Lead

Faculty of Medicine and Health

Orcid identifier0000-0001-9028-8682 (opens in a new tab)⁠
  • Clinical Lead
    Faculty of Medicine and Health

RESEARCH INTERESTs

  • Design & management of Phase II/III Clinical Trials
  • Evidence based medicine
  • Gastrointestinal & Rare Cancers
  • Evaluating benefits versus harms of treatment

FUNDED RESEARCH

  • GRANT
    Biliary Tract Registry Development
    Monash University1 Jul 2023
    People funded by this grant:
    • Sjoquist K
  • GRANT
    Repurposing valproate for the treatment of colorectal cancer
    Medical Research Future Fund1 Jun 2021 - 31 May 2027
    People funded by this grant:
    • Tebbutt N,
    • Mariadason J,
    • Tie J,
    • Sjoquist K,
    • Price T
  • GRANT
    AGITG and Scandinavian Sarcoma Group International Trial Collaboration. SSG XXII: International randomised phase III multicenter study of 3 v 5 years of adjuvant imatinib as treatment of patients with operable GIST with high risk for recurrence
    Medical Research Future Fund1 May 2021 - 30 Apr 2027
    People funded by this grant:
    • Zalcberg J,
    • Sjoquist K,
    • Tebbutt N,
    • Yip D,
    • Desai J
  • GRANT
    Radiological And subjective measures of Nutrition, Diet and sarcOpenia - a Masterplan Substudy(RANDoMS)
    AGITG1 Jan 2021
    People funded by this grant:
  • GRANT
    Understanding resistance and sensivity to PARP inhibitors in Homologous Recombination deficient (HRD) high grade serous ovarian cancer; translational research from the EMBRACE clinical trial
    Australia New Zealand Gynaecological Oncology Group1 Jan 2018
    People funded by this grant:
    • Sjoquist K
  • GRANT
    Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations
    Cancer Australia17 Apr 2017 - 16 Apr 2020
    People funded by this grant:
    • Mileshkin L,
    • Lee CK,
    • Scott C,
    • Wilcken N,
    • Sjoquist K
  • GRANT
    MoST - The Cancer Molecular Screening and Therapeutics Study
    Pfizer Australia Pty Ltd1 Jul 2016
    People funded by this grant:
    • Sjoquist K
  • GRANT
    Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 Trial)
    Cancer Australia1 Mar 2016
    People funded by this grant:
    • Maddern G,
    • Tebbutt N,
    • Merrett ND,
    • Shannon J,
    • Sjoquist K
  • GRANT
    REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers
    Cancer Australia9 Jun 2014
    People funded by this grant:
    • Shannon C,
    • Quinn M,
    • Yip S,
    • Bowtell DDL,
    • Martyn J
  • GRANT
    PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
    Cancer Australia1 Jun 2014
    People funded by this grant:
    • Beale P,
    • Sjoquist K,
    • Friedlander M
  • GRANT
    Does Palliative Chemotherapy Palliate Measuring symptom benefit in recurrent ovarian cancer using patient reported outcomes: The Symptom Benefit Study
    National Health and Medical Research Council (NHMRC)1 Jan 2014 - 31 Dec 2015
    People funded by this grant:
    • Ledermann J,
    • O'Connell R,
    • Oza A,
    • King M,
    • Lee CK
  • GRANT
    A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101)
    Ovarian Cancer Research Foundation1 Jul 2013
    People funded by this grant:
    • Sjoquist K,
    • Martyn J,
    • Friedlander M
  • GRANT
    Technical services of a genomic cancer clinical trial initiative (GCCTI) to develop mutation-specific cancer clinical trials protocols
    Cancer Australia1 Jul 2013
    People funded by this grant:
  • GRANT
    Value of serum levels of Inhibin A, inhibin B, total inhibin and anti- Mullerian Hormone ( AMH) in measuring response of recurrent Granulosa cell tumours to Anastrazole
    Ovarian Cancer Research Foundation1 Jul 2013
    People funded by this grant:
    • Robertson D,
    • BURGER HG,
    • Friedlander M,
    • Martyn J,
    • Sjoquist K
  • GRANT
    ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer
    Cancer Australia4 Mar 2013
    People funded by this grant:
    • Ledermann J,
    • Beale P,
    • Clamp A,
    • Mileshkin L,
    • Dean A
  • GRANT
    Development and operational support for ANZGOG through the NHMRC Clinical Trials Centre: A NSW lead initiative.
    Cancer Institute NSW1 Jan 2013
    People funded by this grant:
    • Brand A,
    • Sjoquist K,
    • Gebski V,
    • Stockler M,
    • Friedlander M
  • GRANT
    REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers
    Cancer Australia1 Jan 2013
    People funded by this grant:
    • Bowtell DDL,
    • Quinn M,
    • Mileshkin L,
    • Sjoquist K,
    • Friedlander M
  • GRANT
    PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer
    Cancer Australia1 Feb 2012
    People funded by this grant:
    • Stockler M,
    • Brand A,
    • Mileshkin L,
    • Khaw P,
    • Sjoquist K
  • GRANT
    Study to evaluate the safety and efficacy of intraperitoneal bevacizumab in patients with advanced platinum refractory or resistant ovarian cancer and symptomatic ascites
    DVC Research1 Jan 2011
    People funded by this grant:
    • Sjoquist K,
    • Martyn J,
    • Friedlander M